Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | HK2 | P52789 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632682 | 0.89 | HDAC3 (0.40) | ERCC1ERCC4HDAC3HDAC1HDAC2 | |
| SCHEMBL24277139 | 0.89 | MEP1B (0.41) | ERCC1ERCC4HDAC3HDAC1HDAC2 | |
| SCHEMBL25438214 | 0.89 | HDAC3 (0.40) | ERCC1ERCC4HDAC3HDAC1HDAC2 | |
| SCHEMBL28400880 | 0.87 | MEN1 (0.45) | ESR1ADORA3NPY1RPTGS2OPRD1 | |
| SCHEMBL19710337 | 0.87 | IAPP (0.42) | ERCC1ERCC4HDAC3HDAC1HDAC2 | |
| SCHEMBL26293601 | 0.85 | SELL (0.41) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL31632680 | 0.85 | SELL (0.41) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL19692994 | 0.84 | ERCC1 (0.46) | ERCC1ERCC4ESR1ADORA3NPY1R | |
| SCHEMBL24277635 | 0.84 | TRPV1 (0.43) | ERCC1ERCC4HDAC3HDAC1HDAC2 | |
| SCHEMBL29521027 | 0.84 | TRPV1 (0.43) | ERCC1ERCC4HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-12421185-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2025-09-23 | — | — | US | disclosed |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022056068-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OFCALIFORNIA (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-10927070-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3672582-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Cedars-Sinai Medical Center (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3468546-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Cedars-Sinai Medical Center (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019040647-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040647-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2017213897-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017213897-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421185-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | ERCC1 1146/4885ERCC4 1092/4885HDAC3 298/4885 |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, RNASE1, TP53 | ERCC1 1146/4885ERCC4 1092/4885HDAC3 298/4885 |
| US-11529338-B2 | Compositions and methods for treating cancer | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | ERCC1 259/4885ERCC4 510/4885HDAC3 1267/4885 |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GLI1, RCC2, BRCA1 | ERCC1 1536/4885ERCC4 3671/4885HDAC3 607/4885 |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | ENPP1, ENPP2, ENPP3 | ERCC1 2167/4885ERCC4 1561/4885HDAC3 2462/4885 |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | ERCC1 259/4885ERCC4 510/4885HDAC3 1267/4885 |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, TP53, RNASE1 | ERCC1 1144/4885ERCC4 1012/4885HDAC3 274/4885 |
| US-10927070-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | ERCC1 1146/4885ERCC4 1092/4885HDAC3 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.